Highlights

Alexion Acquires First Potential Treatment for Patients with Hypophosphatasia (HPP)

Alexion Acquires First Potential Treatment for Patients with Hypophosphatasia (HPP)

Alexion is accelerating the development of asfotase alfa , a first-in-class targeted enzyme replacement therapy in Phase 2 clinical trials for Hypophosphatasia (HPP). HPP is an ultra-rare, genetic and life-threatening metabolic disease with no effective treatment options. Read more

Alexion Ranked #2 on Forbes Most Innovative Companies List

Alexion Ranked #2 on Forbes Most Innovative Companies List

Alexion has been named #2 in Forbes’ annual ranking of The World’s Most Innovative Companies. At Alexion we are committed to transforming the lives of patients with severe and life-threatening ultra-rare disorders and we are honored to receive this recognition for our work.

Alexion Celebrates Rare Disease Day 2013

Alexion Celebrates Rare Disease Day 2013

Alexion joins the European Organization for Rare Diseases (EURORDIS), the National Organization for Rare Disorders (NORD) and patient organizations worldwide in celebrating Rare Disease Day 2013, a global effort to focus attention on rare diseases, their profound impact on patients, and the need for improved diagnosis and treatment. Read more